Search / Trial NCT00000867

A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of December 08, 2024

Completed

Keywords

Drug Therapy, Combination Administration, Oral Aids Dementia Complex Zidovudine Anti Hiv Agents Memantine

ClinConnect Summary

The signs and symptoms of the AIDS Dementia Complex can be alleviated by zidovudine (ZDV). However, ZDV therapy has been associated with significant toxicities, particularly bone marrow suppression. The efficacy of ZDV appears to decrease during the second and third years of therapy. It is not known whether this reflects cumulative toxicity. In addition, the efficacy of other antiretroviral agents remains uncertain. Hence, adjunctive therapy for cognitive and motor symptoms of AIDS is important.

Patients will be randomized to one of the following 2 arms:

Arm 1 receives memantine plus conc...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • You may be eligible for this study if you:
  • Are HIV positive.
  • Have been diagnosed with AIDS dementia complex (ADC).
  • Have an estimated IQ of at least 70 (before the onset of ADC) or the ability to read at a 6th grade level.
  • Have impaired mental skills.
  • Are age18 or older.
  • Exclusion Criteria
  • You will not be eligible for this study if you:
  • Have a history of a neurologic disease unrelated to HIV infection.
  • Have a history of chronic seizures or head injuries.
  • Have a history of central nervous system infections.
  • Have certain cancers.
  • Have any psychiatric illness.
  • Have an active AIDS-defining opportunistic infection.
  • Are pregnant or breast-feeding.

Trial Officials

Bradford Navia

Study Chair

Richard Price

Study Chair

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Los Angeles, California, United States

San Francisco, California, United States

Miami, Florida, United States

Honolulu, Hawaii, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Boston, Massachusetts, United States

Boston, Massachusetts, United States

Omaha, Nebraska, United States

Buffalo, New York, United States

New York, New York, United States

Rochester, New York, United States

Philadelphia, Pennsylvania, United States

Seattle, Washington, United States

St. Louis, Missouri, United States

Honolulu, Hawaii, United States

Lexington, Kentucky, United States

New York, New York, United States

New York, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials